Clinical Trial Update: CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating CYT107 following Provenge treatment in metastatic castration-resistant prostate cancer; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CYT107 (CYT107)
• PROVENGE (sipuleucel-T)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-11